The presence of TP53 mutations in HNSCC has been associated with poorer prognosis, including reduced survival rates and increased risk of disease recurrence, especially in the context of surgical and radiotherapy treatments (17). This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.